BioCryst Pharma Analyst Ratings
BioCryst Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/04/2023 | 323.73% | HC Wainwright & Co. | → $30 | Reiterates | Buy → Buy |
| 08/03/2023 | 69.49% | Needham | $14 → $12 | Reiterates | → Buy |
| 07/13/2023 | 41.24% | B of A Securities | → $10 | Upgrades | Neutral → Buy |
| 05/04/2023 | 27.12% | RBC Capital | → $9 | Reiterates | → Sector Perform |
| 05/04/2023 | 97.74% | Needham | → $14 | Reiterates | → Buy |
| 04/20/2023 | 41.24% | Evercore ISI Group | $13 → $10 | Maintains | Outperform |
| 04/20/2023 | 97.74% | Needham | → $14 | Reiterates | → Buy |
| 03/14/2023 | 41.24% | RBC Capital | → $10 | Reiterates | → Sector Perform |
| 02/22/2023 | 125.99% | JMP Securities | → $16 | Reiterates | → Market Outperform |
| 02/22/2023 | 97.74% | Needham | → $14 | Upgrades | Hold → Buy |
| 02/22/2023 | 323.73% | HC Wainwright & Co. | → $30 | Reiterates | → Buy |
| 11/02/2022 | 125.99% | Evercore ISI Group | → $16 | Upgrades | In-Line → Outperform |
| 11/02/2022 | 83.62% | RBC Capital | $14 → $13 | Maintains | Sector Perform |
| 08/08/2022 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 08/05/2022 | 97.74% | Barclays | $12 → $14 | Maintains | Equal-Weight |
| 08/05/2022 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 08/05/2022 | 97.74% | Evercore ISI Group | → $14 | Downgrades | Outperform → In-Line |
| 04/18/2022 | 83.62% | Barclays | $22 → $13 | Downgrades | Overweight → Equal-Weight |
| 04/12/2022 | 97.74% | RBC Capital | $16 → $14 | Maintains | Sector Perform |
| 04/11/2022 | 97.74% | B of A Securities | → $14 | Downgrades | Buy → Neutral |
| 04/11/2022 | 125.99% | Oppenheimer | $20 → $16 | Maintains | Outperform |
| 12/10/2021 | 125.99% | Oppenheimer | → $16 | Initiates Coverage On | → Outperform |
| 11/04/2021 | 97.74% | RBC Capital | $16 → $14 | Maintains | Sector Perform |
| 11/04/2021 | 140.11% | Barclays | $21 → $17 | Maintains | Overweight |
| 08/06/2021 | 224.86% | JMP Securities | $22 → $23 | Maintains | Market Outperform |
| 08/06/2021 | — | Jefferies | Downgrades | Buy → Hold | |
| 08/06/2021 | 125.99% | RBC Capital | $13 → $16 | Maintains | Sector Perform |
| 08/06/2021 | 196.61% | Barclays | $20 → $21 | Maintains | Overweight |
| 08/06/2021 | 323.73% | HC Wainwright & Co. | $18 → $30 | Maintains | Buy |
| 08/03/2021 | 196.61% | Cantor Fitzgerald | → $21 | Initiates Coverage On | → Overweight |
| 03/24/2021 | 168.36% | HC Wainwright & Co. | $14 → $19 | Maintains | Buy |
| 01/22/2021 | 27.12% | RBC Capital | $7 → $9 | Maintains | Sector Perform |
| 12/07/2020 | 97.74% | HC Wainwright & Co. | $13 → $14 | Maintains | Buy |
| 11/24/2020 | 69.49% | Evercore ISI Group | → $12 | Initiates Coverage On | → Outperform |
| 06/17/2020 | — | BTIG | Initiates Coverage On | → Neutral | |
| 05/05/2020 | -1.13% | Barclays | $4 → $7 | Upgrades | Equal-Weight → Overweight |
| 11/15/2019 | — | B of A Securities | Upgrades | Neutral → Buy | |
| 05/24/2019 | -36.44% | RBC Capital | $16 → $4.5 | Downgrades | Outperform → Sector Perform |
| 04/02/2019 | 12.99% | Barclays | $6 → $8 | Maintains | Equal-Weight |
| 04/02/2019 | 154.24% | JMP Securities | $16 → $18 | Maintains | Market Outperform |
| 11/16/2018 | 111.86% | Piper Sandler | → $15 | Reinstates | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 08/04/2023 | 323.73% | HC Wainwright公司 | →$30 | 重申 | 购买→购买 |
| 08/03/2023 | 69.49% | 李约瑟 | $14→$12 | 重申 | →购买 |
| 07/13/2023 | 41.24% | B of A证券 | →$10 | 升级 | 中性→购买 |
| 05/04/2023 | 27.12% | 加拿大皇家银行资本 | →$9 | 重申 | →行业表现 |
| 05/04/2023 | 97.74% | 李约瑟 | →$14 | 重申 | →购买 |
| 04/20/2023 | 41.24% | Evercore ISI集团 | $13→$10 | 维护 | 跑赢大盘 |
| 04/20/2023 | 97.74% | 李约瑟 | →$14 | 重申 | →购买 |
| 03/14/2023 | 41.24% | 加拿大皇家银行资本 | →$10 | 重申 | →行业表现 |
| 02/22/2023 | 125.99% | JMP证券 | →$16 | 重申 | →市场跑赢大盘 |
| 02/22/2023 | 97.74% | 李约瑟 | →$14 | 升级 | 持有→购买 |
| 02/22/2023 | 323.73% | HC Wainwright公司 | →$30 | 重申 | →购买 |
| 11/02/2022 | 125.99% | Evercore ISI集团 | →$16 | 升级 | 线内→表现优异 |
| 11/02/2022 | 83.62% | 加拿大皇家银行资本 | $14→$13 | 维护 | 行业表现 |
| 2022/08/08 | - | 奥本海默 | 评级下调 | 超越→表现 | |
| 08/05/2022 | 97.74% | 巴克莱 | $12→$14 | 维护 | 等重 |
| 08/05/2022 | - | 奥本海默 | 评级下调 | 超越→表现 | |
| 08/05/2022 | 97.74% | Evercore ISI集团 | →$14 | 评级下调 | 胜过→同线 |
| 04/18/2022 | 83.62% | 巴克莱 | $22→$13 | 评级下调 | 超重→等重 |
| 04/12/2022 | 97.74% | 加拿大皇家银行资本 | $16→$14 | 维护 | 行业表现 |
| 04/11/2022 | 97.74% | B of A证券 | →$14 | 评级下调 | 购买→中性 |
| 04/11/2022 | 125.99% | 奥本海默 | $20→$16 | 维护 | 跑赢大盘 |
| 2021年12月10日 | 125.99% | 奥本海默 | →$16 | 开始承保 | →跑赢大盘 |
| 11/04/2021 | 97.74% | 加拿大皇家银行资本 | $16→$14 | 维护 | 行业表现 |
| 11/04/2021 | 140.11% | 巴克莱 | $21→$17 | 维护 | 超重 |
| 08/06/2021 | 224.86% | JMP证券 | $22→$23 | 维护 | 市场表现强于大盘 |
| 08/06/2021 | - | 杰富瑞 | 评级下调 | 购买→Hold | |
| 08/06/2021 | 125.99% | 加拿大皇家银行资本 | $13→$16 | 维护 | 行业表现 |
| 08/06/2021 | 196.61% | 巴克莱 | $20→$21 | 维护 | 超重 |
| 08/06/2021 | 323.73% | HC Wainwright公司 | $18→$30 | 维护 | 买 |
| 08/03/2021 | 196.61% | 康托·菲茨杰拉德 | →$21 | 开始承保 | →超重 |
| 03/24/2021 | 168.36% | HC Wainwright公司 | $14→$19 | 维护 | 买 |
| 2021/01/22 | 27.12% | 加拿大皇家银行资本 | $7→$9 | 维护 | 行业表现 |
| 12/07/2020 | 97.74% | HC Wainwright公司 | $13→$14 | 维护 | 买 |
| 11/24/2020 | 69.49% | Evercore ISI集团 | →$12 | 开始承保 | →跑赢大盘 |
| 06/17/2020 | - | BTIG | 开始承保 | →中性 | |
| 05/05/2020 | -1.13% | 巴克莱 | $4→$7 | 升级 | 等重→超重 |
| 2019年11月15日 | - | B of A证券 | 升级 | 中性→购买 | |
| 2019年05月24日 | -36.44% | 加拿大皇家银行资本 | $16→$4.5 | 评级下调 | 跑赢→板块表现 |
| 2019年02月04日 | 12.99% | 巴克莱 | $6→$8 | 维护 | 等重 |
| 2019年02月04日 | 154.24% | JMP证券 | $16→$18 | 维护 | 市场表现强于大盘 |
| 2018年11月16日 | 111.86% | 派珀·桑德勒 | →$15 | 恢复 | →超重 |
What is the target price for BioCryst Pharma (BCRX)?
BioCryst Pharma(BCRX)的目标价格是多少？
The latest price target for BioCryst Pharma (NASDAQ: BCRX) was reported by HC Wainwright & Co. on August 4, 2023. The analyst firm set a price target for $30.00 expecting BCRX to rise to within 12 months (a possible 323.73% upside). 17 analyst firms have reported ratings in the last year.
生物冷冻制药公司(纳斯达克代码：BCRX)的最新目标价是由HC Wainwright&Co.于2023年8月4日报道的。这家分析公司将目标价定为30美元，预计BCRX将在12个月内上涨至(可能上涨323.73%)。过去一年，17家分析公司公布了评级。
What is the most recent analyst rating for BioCryst Pharma (BCRX)?
BioCryst Pharma(BCRX)的最新分析师评级是什么？
The latest analyst rating for BioCryst Pharma (NASDAQ: BCRX) was provided by HC Wainwright & Co., and BioCryst Pharma reiterated their buy rating.
纳斯达克(代码：BCRX)的最新分析师评级由HC Wainwright&Co.提供，BioCryst Pharma重申其买入评级。
When is the next analyst rating going to be posted or updated for BioCryst Pharma (BCRX)?
BioCryst Pharma(BCRX)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioCryst Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioCryst Pharma was filed on August 4, 2023 so you should expect the next rating to be made available sometime around August 4, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与BioCryst Pharma的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。BioCryst Pharma的上一次评级是在2023年8月4日提交的，所以你应该预计下一次评级将在2024年8月4日左右的某个时候提供。
Is the Analyst Rating BioCryst Pharma (BCRX) correct?
分析师对BioCryst Pharma(BCRX)的评级正确吗？
While ratings are subjective and will change, the latest BioCryst Pharma (BCRX) rating was a reiterated with a price target of $0.00 to $30.00. The current price BioCryst Pharma (BCRX) is trading at is $7.08, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的BioCryst Pharma(BCRX)评级被重申，目标价在0.00美元至30.00美元之间。BioCryst Pharma(BCRX)目前的交易价格为7.08美元，在分析师的预测范围内。